Biocryst Pharmaceuticals Inc (BCRX)

01:36 AM

T-cell Lymphoma Market Report with Detailed Study Analysis - openPR.com

01:36 AM

Nov 03, 2025

BioCryst Pharmaceuticals (BCRX): Forecasts Call for 56.3% Annual Earnings Growth Heading Into Earnings Season - Yahoo Finance

Nov 03, 2025

Nov 03, 2025

BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ... - Yahoo Finance

Nov 03, 2025

Nov 03, 2025

BioCryst Pharmaceuticals, Inc. Appoints Ron Dullinger as Chief Commercial Officer, Effective January 1, 2026 - MarketScreener

Nov 03, 2025

Nov 03, 2025

BioCryst Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2025 - MarketScreener

Nov 03, 2025

Nov 03, 2025

BioCryst: Q3 Earnings Snapshot - CTPost

Nov 03, 2025

Nov 03, 2025

BioCryst Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Nov 03, 2025

Nov 03, 2025

BioCryst (BCRX) Q3 2025 Earnings Call Transcript - AOL.com

Nov 03, 2025

Nov 03, 2025

Earnings call transcript: BioCryst Q3 2025 earnings beat estimates, stock dips - Investing.com

Nov 03, 2025

Nov 03, 2025

BioCryst Pharmaceuticals (BCRX) Reports Strong Q3 Earnings, Rais - GuruFocus

Nov 03, 2025

Nov 03, 2025

BioCryst Reports Q3 2025 Financial Growth and Strategy - TipRanks

Nov 03, 2025

Nov 03, 2025

BioCryst (BCRX) Revenue Falls Short but Strategic Moves Drive Fu - GuruFocus

Nov 03, 2025

Nov 03, 2025

BioCryst (BCRX) Adjusts 2025 Financial Projections for ORLADEYO - GuruFocus

Nov 03, 2025

Nov 03, 2025

Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q3 Revenue $159.4M, vs. FactSet Est of $163.0M - MarketScreener

Nov 03, 2025

Nov 03, 2025

Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Posts Q3 Adjusted EPS $0.16 per Share, vs. FactSet Est of $0.07 - MarketScreener

Nov 03, 2025

Nov 03, 2025

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update - Bluefield Daily Telegraph

Nov 03, 2025

Nov 03, 2025

Will BioCryst Pharmaceuticals Inc. stock maintain growth storyQuarterly Growth Report & AI Powered Market Entry Ideas - newser.com

Nov 03, 2025

Nov 03, 2025

When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Short Interest & AI Driven Stock Reports - newser.com

Nov 03, 2025

Nov 03, 2025

Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolution2025 Top Decliners & Consistent Return Investment Signals - newser.com

Nov 03, 2025

Nov 03, 2025

Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Volatility Report & Technical Entry and Exit Tips - newser.com

Nov 03, 2025

Nov 03, 2025

What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackJuly 2025 Spike Watch & Real-Time Chart Breakout Alerts - newser.com

Nov 03, 2025

Nov 03, 2025

Will BioCryst Pharmaceuticals Inc. stock attract ESG investors2025 Technical Patterns & Precise Buy Zone Identification - newser.com

Nov 03, 2025

Nov 02, 2025

Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Dividend Review & Technical Entry and Exit Alerts - newser.com

Nov 02, 2025

Nov 02, 2025

Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com

Nov 02, 2025

Nov 01, 2025

Y Intercept Hong Kong Ltd Increases Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat

Nov 01, 2025

Oct 31, 2025

Promising Biotech Stocks To Follow TodayOctober 14th - MarketBeat

Oct 31, 2025

Oct 30, 2025

# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com

Oct 30, 2025

Oct 29, 2025

BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq

Oct 29, 2025

Oct 29, 2025

BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com

Oct 29, 2025

Oct 28, 2025

Why BioCryst Shares Plunged - AOL.com

Oct 28, 2025